Next 10 |
home / stock / arqt / arqt articles
Shares of Lexeo Therapeutics (NASDAQ: LXEO) lost 26% on Monday after it reported positive interim data from two cohorts of the phase I/II SUNRISE-F...
Immutep Limited (NASDAQ: IMMP) jumped 14.9% after it announced positive results from cohort B of the late-stage TACTI-003 (KEYNOTE-PNC-34) stu...
On Tuesday, the FDA approved Arcutis Biotherapeutics Inc’s (NASDAQ:ARQT) supplemental new drug application (sNDA) for Zoryve (roflumilast) cr...
Shares of Argenx (NASDAQ: ARGX) rose nearly 4% on Friday after management announced that the FDA approved its subcutaneously administered Vyvgart H...
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday. Shares of Vanda Pharmaceuticals Inc. (N...
Avidity Biosciences (NASDAQ: RNA) announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlo...
WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical c...
Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday's session after the company reported first-quarter financial ...
U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday. Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wedn...
News, Short Squeeze, Breakout and More Instantly...
Arcutis Biotherapeutics Inc. Company Name:
ARQT Stock Symbol:
NASDAQ Market:
Arcutis Biotherapeutics Inc. Website:
Approximately 40% of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp Once-daily ZORYVE foam significantly improved both scalp and body psoriasis in a Phase 2b and a pivotal Phase 3 trial Data also show rapid reduction in scalp itc...
WESTLAKE VILLAGE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a virtual Key Opinion Leader (KOL) event fea...
ZORYVE cream provides rapid relief, with efficacy, safety, and tolerability demonstrated up to 56 weeks of treatment ZORYVE cream rapidly and significantly reduces itch, the most bothersome symptom of atopic dermatitis (AD) Once-daily cream is for use anywhere on the body for any duration...